Medical Condition News

RSS
Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Salk researchers advance sonogenetics technology for treating neurological conditions

Salk researchers advance sonogenetics technology for treating neurological conditions

Common antibodies associated with myocardial infarction

Common antibodies associated with myocardial infarction

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

New approach may lead to better diagnostic techniques for autoimmune disorders

New approach may lead to better diagnostic techniques for autoimmune disorders

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Volunteering for peer counseling programs benefits people with lupus

Volunteering for peer counseling programs benefits people with lupus

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Researchers identify common genetic connection in lung conditions

Researchers identify common genetic connection in lung conditions

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Stress related to social stigma negatively impacts mental health of autistic people

Stress related to social stigma negatively impacts mental health of autistic people

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

People with periodontal disease less likely to reach healthy blood pressure ranges

People with periodontal disease less likely to reach healthy blood pressure ranges

Study findings could set new standard of care for advanced anal cancer

Study findings could set new standard of care for advanced anal cancer

Duration of respiratory disturbances may better predict mortality risk from OSA

Duration of respiratory disturbances may better predict mortality risk from OSA

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.